A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

NCT05076149 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

597

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: VX-121/TEZ/D-IVA
DRUG: ELX/TEZ/IVA
DRUG: IVA
DRUG: Placebo (matched to VX-121/TEZ/D-IVA)
DRUG: Placebo (matched to ELX/TEZ/IVA)
DRUG: Placebo (matched to IVA)

Sponsor

Vertex Pharmaceuticals Incorporated